Corporate Strategy

Mid-Term Plan

Mid-Term Management Plan (Fiscal Years Ending March 31, 2024 to 2026)

* The table can be scrolled horizontally.

Group Key Actions (GKA) under the Mid-Term Management Plan			Domain

	1	Enhance competitiveness and expand markets through innovation in diagnostics business domain	A
	2	Accelerate commercialization centered on genetic testing in the domain of personalized medicine	B
	3	Create a new business model in the domains of prevention and self-medication	C
	4	Accelerate business growth in the therapeutic domain, centered on the medical robotics business	D
	5	Realize a circular resource value chain and transform with a view to solving social issues	AB CD
	6	Enhance corporate value by strengthening human capital and management base	-

*The business domain of Long-Term Corporate Strategy 2033

Financial Targets　(Fiscal Year Ending March 31, 2026)

Financial Targets (Fiscal year ending March 31, 2026)

**Financial Targets**
(Fiscal year ending
March 31, 2026)
Net Sales
¥560.0billion
Operating Profit
¥112.0billion
ROE
16.0%

Assumed exchange rates during the period of the mid-term management plan：
1USD=¥133.0, 1EUR=¥143.0, 1CNY=¥19.2

Back to "Corporate Strategy"